Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.

Trial Details

NCT ID
NCT06745882
Phase
PHASE2
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Cisplatin
  • Carboplatin
  • Pemetrexed
  • Pembrolizumab
  • Abraxane
  • Paclitaxel
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Salisbury, Maryland, United States|38.36067,-75.59937
  • The Bronx, New York, United States|40.84985,-73.86641
  • Memphis, Tennessee, United States|35.14953,-90.04898

Key Eligibility Criteria

  • Be willing and able to provide written informed consent/assent.
  • Must be ≥ 18 years of age on day of signing informed consent.
  • Be Black / African American per self-report.
  • Have an ECOG performance status of 0- 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →